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To Investigate a possible cause-and-effect relationship be­
tween sexually transmitted diseases and cervical cancer, we 
performed a sero-epidemiological study on the presence of 
antibodies against a number of sexually transmitted agents 
(STAs) in patients with cervical cancer and their matched 
controls. In this study, we used serological techniques to  
investigate the presence of antibodies to cytomegalovirus, 
herpes simplex virus type 2, human immunodeficiency virus, 
Chlamydia trachomatis, Treponema pallidum and human papil­
lomavirus (HPV) early protein E7 in sera from patients with 
cervical cancer, cervical intra~epithelial neoplasia and individu­
ally matched, healthy controls. The presence of antibodies to  
infectious agents other than HPV appeared not to be associ­
ated with risk of cervical neoplasia in either univariate or 
multivariate analysis. A fter adjustment for cytology, school­
ing and presence of H PV D N A  in cervical scrapes, there was a 
significantly higher prevalence of antibodies to HPV-16 E7 
protein in sera from patients with cervical cancer (OR = 3.6, 
95% Cl 1,0-12.9) than in healthy controls. The highest antibody 
prevalence was found among HPV-16 DNA-positive cervical 
cancer patients (33%). O ur results indicate that in these study 
groups past infections with the STA considered seems to be 
of no apparent relevance for cervical carcinogenesis and that 
the HPV-16 anti-E7 response appears to be associated with 
cervical cancer. Int.), Cancer 73:781 -785, 1997.
© 1997 Wiley-Liss, Inc,
Carcinoma of the cervix is the second most common type of 
cancer affecting women worldwide and the leading cause of death 
from cancer among women in developing countries (CDC, 1989). 
Worldwide death estimates of 450,000-500,000 women have been 
reported, of which almost 80% occur in developing countries,
Well-documented epidemiological studies have shown that early 
age at first sexual intercourse, a history of multiple partners, 
increased parity and a history of sexually transmitted diseases 
(STDs) are among the strongest risk factors associated with 
cervical intra-epithelial. neoplasia (CIN) and cancer (Bosch et a l ,  
1992; Schiffman, 1992).
This association of cervical cancer with sexual activity has been 
recognized since the early nineteenth century. The work of Beral 
(1974) presented important new observations and provided addi­
tional evidence that exposure to sexually transmitted infection was 
an important determinant for cervical cancer. In the 1960s and 
1970s, herpes simplex virus type 2 (HSV-2) infections were 
implicated directly in human cervical carcinogenesis; however, the 
lack of association o f this virus with the development of cervical 
neoplasia in prospective epidemiological studies shifted investiga­
tions to human papillomavirus (HPV) (Vonka et al> 1984).
Epidemiological studies using PCR-based techniques have dem ­
onstrated clearly that certain types of HPV, mainly HPV-16, are the 
primary causative agents o f  cervical cancer and its precursor 
lesions (Melchers et a l ,  1994; Munoz et aL, 1992). HPV DNA is 
detected in 80-90% of cervical carcinomas, and the majority of 
those cases harbor HPV* 16.
Although a large number of women without cervical abnormali­
ties are infected with HPV, only a minority of these women will 
ultimately develop cervical cancer. Consequently, one or more
additional events are necessary besides HPV infection for progres­
sion to malignancy (Bosch et a l ,  1992),
Several sexually transmitted agents (STAs) other than H PV  have 
been suggested independently to be implicated in the initiation of 
carcinogenesis, including Afa iss e ria gono rrh oeae, Trepon en ut pa 11- 
idum, Chlamydia trachomatis, HSV-2, cytomegalovirus (CMV) 
and Trichomonas vaginalis (Jha et a l,  1993), but the significance 
of these associations remains to be established. Som e studies have 
reported that women infected with human immunodeficiency virus 
(HIV) are more likely to develop cervical dysplasia (Ferrera et a l,  
1997), and this association is stronger for women with a low C D 4+ 
T-lymphocyte count (M aiman et aL, 1990).
Epidemiological data show associations in which cervical cancer 
and its precursor lesions are promoted by at least one and perhaps 
several STDs. Serological methods which accurately reflect the 
presence or absence o f past exposures to these individual agents are 
an ideal way to assess exposure in epidemiological studies of 
cervical neoplasia.
Cervical cancer is the most prevalent cancer of women in 
Honduras» and STDs are highly prevalent in the country. Early 
exposure of the immature cervical epithelium to STDs, the trauma 
of repeated childbirth and multiple sexual partners in women 
whose defense factors are im paired by malnutrition add to the risk 
of developing cervical dysplasias in the country:
To investigate a possible cause-and-effect relationship between 
STDs and cervical cancer, we performed a sero-epidemiological 
study on the presence o f antibodies against a number o f STAs in 




This study is part o f  a larger case-control study on cervical 
cancer in Honduras. W omen participating in the study were derived 
from public hospitals, communal health-care centers, family- 
planning and gynecology clinics serving the population o f Te­
gucigalpa, the capital city o f Honduras. Women with cervical 
lesions were referred to San Felipe General Hospital, a referral 
center for such patients in the country, where they were enrolled 
into the study. Cases were women aged 20-65 years with different 
grades of histologically confirmed CIN and invasive cervical 
cancer diagnosed between 1993 and 1995. Controls with a normal 
cervix, two per case, were selected from the clinic where the case 
was first seen and matched to cases according to a 5-year interval of
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a He, with a maximum recruitment time of 1 month from the date of
c
case diagnosis. These women attended these clinics to receive 
routine cervical cytological screening. In general, women either 
may be referred for screening by their doctor or may request 
screening on their own.
In both groups, after formal consent, a smear was made for 
cytological examination, which was classified according to the CIN 
classification system (OPS, 1990). The remaining material and an 
additional scrape were collected in 5 ml PBS, 0.05% merthiolate, 
pH 7.5, and used for DNA extraction and PCR HPV assays. A 
10-15 ml blood sample was taken from each woman to measure 
antibodies against the most common STA. Sera were separated, 
divided into aliquots and stored at -20°C.
All study subjects were interviewed using a structured question­
naire given by specially trained personnel for the project. Informa­
tion was obtained on demographic variables, sexual and reproduc­
tive histories and previous cytological screening. Screening events 
for the analysis were computed by reducing by 1 if the most recent 
cytological screening was reported to have taken place within 12 
months prior to the interview.
HPV markers
DNA extraction and HPV-PCR assays. HPV DNA sequences 
were sought in cytological specimens obtained by cervical scraping 
by PCR amplification. Briefly, scrapes were vortexed, centrifuged, 
washed, pelleted and resuspended in 0.5 ml PBS. DNA extraction 
was performed according to the standard SDS-proteinase K-phenoI- 
chloroform method, as previously described (Melchers etaL, 1989).
All samples were pre-screened with the (3-globin primers 
PC03/PC04 (Saiki et ah, 1985) to assess sample integrity. Then, a 
general primer-mediated PCR (GP-PCR) strategy was followed for 
analysis of samples for the presence of HPV DNA. The overall 
presence of HPV was assessed using a general primer set (MY 11, 
primer for the positive strand, and MY09, primer for the negative 
strand) directed against the LI open reading frame, which amplifies 
a fragment of about 450 bp of at least 25 distinct genital HPVs as 
well as unidentified HPV types (HPV X) (Manos et al, 1989)* 
After low-stringency Southern blot analysis with a generic probe 
mix, PCR-positive specimens were subjected to consecutive HPV 
type-specific PCRs (TS-PCRs) (Melchers et a l , 1989). Each 
amplification test in both GP-PCR and TS-PCR included one tube 
with Siha cells as a positive control and one tube with distilled 
water as a negative control. To prevent contamination, strict spatial 
partitioning of the different technical steps of the PCR was done, 
and the recommendations of Kwok and Higuchi (1989) were 
followed.
Enzyme immunoassay with synthetic peptide. A synthetic peptide 
of HPV-16 E7 protein (amino acids 6-35) was used in an ELISA to
screen a subset of 147 CINs and invasive cervical cancers and 294 
controls for antibodies against HPV-16 E7 (Baay et al., 1995). The 
cut-off value was obtained from the testing of 29 children’s sera on 
E7/6-35, using the mean absorption plus three times the standard 
deviation. Each sample was tested in triplicate, and known positive, 
negative and borderline-positive sera were included in each plate. 
Results were expressed as a ratio (mean absorbance of patient 
serum divided by mean absorbance of cut-off serum). Sera showing 
a ratio higher than 1.0 were considered positive.
Serological detection o f STDs
The presence of serum IgG antibodies (indicative of past 
infection) to the following infectious agents was determined by 
commercially available ELISA kits: C. trachomatis (Chlamydien 
IgG rELISA; Medac, Hamburg, Germany), which detects antibod­
ies against Chlamydia-specific iipopolysaccharides (LPSs); CMV 
(Gull, Salt Lake City, UT), which shows high sensitivity and 
specificity; HSV-2 (Gull), which uses a purified HSV-2 antigen (St, 
Jeor strain); HIV-l (HIVAB-HIV-1 El A; Abbott, North Chicago, 
IL), with positive results confirmed by Western blot (Cambridge 
Biotech, Worcester, MA). Antibodies to syphilis were tested by a 
microhemagglutination assay (TPHA; Fujirebio, Tokyo, Japan) 
specific for antibodies against T. pallidum in human serum.
Statistical analysis
To estimate the association between cervical cancer and the 
different markers of STDs, we used conditional logistic regression 
to compare the prevalence of STAs in cases and controls and to 
calculate odds ratios (ORs) and 95% confidence intervals (CIs). A 
set of adjustment factors were included in the model to control for 
possible confounding effects.
RESULTS
A subset of serum samples from a total of 667 women included 
in the case-control study were analyzed for an association between 
antibodies to various STAs and cervical neoplasia. For the remain­
ing women, not enough serum sample was available for testing. 
Patients and controls were similar regarding age. The mean age for 
cases was 45.9 years and that for controls, 45.2 years; less than 
20% of cases and controls reported having had 4 or more sexual 
partners. Demographic data indicated that a large proportion of our 
study subjects were economically disadvantaged, with family 
incomes of less than $1,000 per year. In general, cases had not 
attained as high an educational level as controls and had a lower 
mean annual income.
Table I shows, for each of the 4 study groups, the total number of 
women examined and the percentages of seroreactivity to each of 5 
antigens, as well as the antibody response to more than one STA.
«
TABLE I -  SEROPREVALENCE OF INFECTIOUS AGENTS IN WOMEN WITH DYSPLASIA,
CERVICAL CANCER AND CONTROLS
CIN I CIN II CIN III Cancer
Agent %  seropositive (N)1 % seropositive (N)1 % seropositive (N)1 %  seropositive (N)1
Cases Controls Cases Controls Cases Controls Cases Controls
CMV 100 100 100 100 95.8 91.7 89.8 94.7
(9) (18) (8) (15) (24) (48) (49) (95)
C. trachomatis 55.6 61.1 62.5 78.6 80 68 70 62.1
(9) (18) (8) (14) (25) (50) (50) (95)
HSV-2 100 100 100 100 100 92 97.9 95.7
T. pallidum
(9) (18) (8) (15) (25) (50) (48) (93)
16.3 9.3 17.1 9.1 8.9 7.0 18.3 11.9
(43) (86) (35) (66) (45) (86) (104) (194)
HIV 4.7 0 5.6 0 0 2.3 0 0,5
Multiple infections2
(43) (86) (36) (67) (45) (86) (104) (195)
11.1 0 37.5 7.1 4.0 4.0 14.3 11.6
(9) (18) (8) (14) (25) (50) (49) (95)
!N = Total number of sera tested from patients and controls - 2C. trachomatis and I  pallidum.
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Prevalence of STA antibodies was generally more common among 
cases than controls, the difference being more marked among the 
CIN III and invasive cancer groups (the exception being antibodies 
to HIV in both groups). Among cases and controls in all groups, the 
most common STA antibodies detected were CMV and HSV-2, 
with a positivity higher than 89.8% and 92%, respectively. 
Antibodies to C. trachomatis were higher in cases of CIN III and 
invasive cancer than in corresponding controls. Syphilis was not a 
rare infection in the entire studied group, with the highest 
seroprevalence encountered in the invasive cancer patients and 
their controls (18.3% and 11.9% for cases and controls, respec­
tively). The presence of antibodies to HIV was more common 
among cases (1.8%) than controls (0.7%), with an overall seroreac- 
tivity of 1.1% in the studied group. Multiple seroreactivity to 
individual agents was exceptionally high for the 8 CIN II cases. 
However, this interactive effect decreased in CIN III and cervical 
cancers patients.
Table II shows the crude ORs and 95% CIs for the presence of 
antibodies to CMV, C. trachomatis, HSV-2 and T pallidum; we 
also assessed any possible increased risk of developing disease 
after adjusting for HPV DNA and other probable confounding 
factors based on our analysis of risk factors (data not shown). This 
analysis gave us the minimal set of risk factors significantly related 
to disease status. This minimal set was different for CIN I/IT, CIN 
III and invasive cancer.
The presence of antibodies to any of the infectious agents tested 
appeared not to be associated with risk of cervical malignancy in 
either univariate or multivariate analysis. A 2-fold increased risk of 
CIN III was observed for women with antibodies to C. trachomatis 
even after adjustment for HPV DNA, though it was statistically not 
significant. In regard to HSV-2 in the invasive cancer group, 
adjusting for HPV DNA alone made the association of HSV-2 and 
disease status disappear. Serological evidence of previous syphilis 
conveyed an increased risk of developing dysplasia and cervical 
cancer. In cervical cancer patients, the risk was still 2-fold higher 
after HPV infection was considered; however, it did not reach 
statistical significance.
To evaluate the association of antibodies against HPV» 16 E7 
protein with CIN I, II, III and invasive cancer patients and their 
matched controls, we tested a subset of their sera in a synthetic 
peptide ELISA (amino acids 6-35). Twenty of the controls did not 
give consistent results on repeated testing. These sera were scored 
as equivocal and excluded from statistical analysis.
On PCR analysis, there were 139 HPV-16-reIated-positive 
subjects (types 16, 31, 33, 35, 52, 58; 85 patients, 54 controls). 
Seventy-five subjects were positive for other HPVs (types 6, 11, 18,
45, 53, 55, 56, 59, 62, 66, 69, X; 31 patients, 44 controls). There 
were 207 subjects in the HPV-negative group (31 patients, 176 
controls). Antibodies to synthetic peptide E7 were detected more
TABLE 11 -  ASSOCIATIONS OF INFECTIOUS AGENTS
WITH RISK OF CERVICAL CANCER
Agent
t
CIN I/II CIN 111 Cervical cancer
OR (95% Cl) OR (95% Cl) OR (95% Cl)





C. tracho­ 0.71 (0.23-2.23) 1.9 (0.6-5.8) 1.37 (0.67-2.82)
matis 0.28 (0.04-2.23)' 
0.24 (0.03-2.08)3
2.0 (0.5—7.9)' 0.95 (0.36-2.50)' 
0.24 (0.04-L45)2
HSV-2 2.3 (0.22-24.4) 
0.80 (0.04-15.1)1 
0.16 (0.0-36.6)2
T. pallidum 2.01 (0.88-4.6) 1.3 (0.3-4.9) '1.84 (0.89-3.8)
1.93 (0.83-4.50)' 1.4 (0.2—9.4)' 2.13(0.94-4.82)'
1.73 (0.72-4.16)3 0.76 (0.20-2.82)2
'Adjusted for presence/absence of HPV,-2Adjusted for HPV, school­
ing and cytology.-3Adjusted for HPV and schooling.
frequently in HPV-16-related-positive patients than in those posi­
tive for other HPVs or HPV DNA-negative. There were 219 
HPV-16~DNA-negative cases with serological response. The major­
ity of control samples in which seroreactivity was revealed did not 
harbor HPV 16.
Table III presents the risk estimates for cervical dysplasias and 
invasive cancer in relation to reactivity to synthetic peptide E7 of 
HPV 16. ORs are presented, adjusted by HPV DNA, schooling and 
previous cytology. Although not statistically significant, the associa­
tion between seroreactivity to HPV-16-derived peptide was related 
more clearly to CIN III and invasive cervical cancer than to the 
mild dysplasias (OR =  1.92, 95% Cl =  0.4-8.6; OR =  1.6, 95% 
C l = 0.8-3.2; OR =  1,27, 95% Cl =  0.3-4.8, respectively). The 
almost 8-fold increased risk conferred to the CIN III group after 
adjustment for the presence of HPV DNA can be explained by the 
fact that only 5 cases in this group had an HPV-negative PCR; 
consequently, this is without statistical relevance. On the contrary, 
a significant increased risk for cervical cancer was noted when 
cytology, schooling and presence of HPV DNA in cervical scrapes 
was taken into consideration (OR =  3.6,95% Cl = 1.0-12.9).
DISCUSSION
The increased awareness of the possible interaction of STDs 
with the development of cervical cancer has special significance for 
Honduras, where these diseases, whose effective control will 
significantly reduce the morbidity and mortality they cause, are 
highly prevalent.
Epidemiological studies have supported the idea that synergism 
between multiple infections may be a cause of the development of 
cervical cancer (Dillner et a i , 1994) and that long-standing 
infections will promote cervical malignancy through chronic 
irritation and, thus, a higher possibility of HPV infection. To gain 
insight for these observations in this country, we examined the role 
of several STAs in cervical neoplasms and the possible co­
operation of HPV with other viruses and bacteria in developing 
genital lesions.
Even though many investigations have focused on STAs and 
their implication in carcinogenesis, no consistent picture has 
emerged for an etiological role of infectious agents other than HPV 
in the development of cervical cancer (Brinton, 1992). Indeed, our 
data suggest that seropo si tivity for CMV, C. trachomatis, HSV-2, T. 
pallidum, HIV and non-HPV multiple infections were not signifi­
cantly more common in women with dysplasia and cervical cancer 
than in controls.
Our findings are similar to the prospective study of Hakamaei a i  
(1993), which reported no association with risk of cervical 
malignancy for such infectious agents as CMV, HSV-2, Epstein- 
Barr virus and N. gonorrhoeas, though they showed a significant 
5-fold increased risk for C. trachomatis and development of 
cervical cancer. Nevertheless, they claimed that this result might
TABLE III -  ANTIBODIES TO HPV-16 E7 PROTEIN IN SERA OF CERVICAL
NEOPLASIA CASES AND CONTROLS
%  Seropositive (N)1 OR OR
Cases Control (95% Cl) (95% Cl)
CIN I 11.8 (17) 12.1 (33) 1.272 1.912
(0.3-4.8) 0
 
» u> 1 OÛ
CIN II 16.7(12) 4.5 (22)
CIN III 15.2 (33) 10.3 (58) 1.92 7.7
(0.4-8.6) (0.7-88.1 )4
Cervical cancer 22.4 (85) 13.7(161) 1.6 3.6
(0.8-3.2) (1.0-12.9)5
lN =  Total number of sera tested from patients and controls,-2CIN 
I/IL-3Adjusted for HPV and schooling.-4Adjusted for HPV.—‘’Adjusted 
for cytology, schooling and HPV.
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have been biased by the C. trachomatis assay cross-reacting with 
antibodies to C. psittaci/C. pneumoniae and by the study popula­
tion sample being too small. In our study, after taking HPV DNA 
status into consideration, a non-significant 2-fold increased risk 
was seen for women with C. trachomatis antibodies in the CIN III 
category. Our analysis could have been hampered by the IgG 
recombinant ELISA used since the Chlamydia-specific fragment of 
the LPS employed as antigen is genus- and not species-specific, 
and we cannot override cross-reaction with C. psittaci/C. pneu­
moniae as well.
Of particular interest is the relationship of risk to infection with 
HSV-2, which has been supported by numerous case-control 
studies examining the relationship between this virus and cervical 
cancer (Brinton, 1992). In a study of STDs and other risk factors for 
cervical dysplasia among southwestern Hispanic and non-Hispanic 
white women, Becker et a l  (1994) found that antibodies to HSV-2 
were associated significantly with dysplasia among non-Hispanic 
whites compared to a lack of association among Hispanic women. 
Muñoz et al. (1995) used type-specific glycoproteins in an HSV-2 
ELISA and, contrary to the results of Hildesheim et a l  (1991), 
concluded that the role of HSV-2 is merely marginal; their results 
did not support the hypothesis that recurrent HSV-2 infections are 
of importance for cervical neoplasia. In our study, the seropreva- 
lence of HSV-2 and CMV was extremely high in both cases and 
controls and was not associated significantly with incidence of 
cervical neoplasms. The apparent association seen for HSV-2 and 
the risk of developing cervical cancer was entirely due to confound­
ing by HPV DNA. We cannot rule out, however, a lack of 
specificity of the assay used to detect HSV-2 infection due to 
possible cross-reactivity with HSV-1.
Infections with 7! pallidum are chronic and exhibit degrees of 
latency. Furthermore, the spectrum of these infections may elicit 
different patterns of antibody response. At present, none of the 
syphilis serological tests are 100% specific for antibodies to T. 
pallidum and positive reactions may be seen in patients infected 
with other pathogenic treponema, as in pinta and yaws, which are 
prevalent in Central America. In our group of subjects, the effect of 
syphilis on the risk of developing cervical cancer disappeared when 
adjustment for previous screening was introduced in the logistic 
model. We can speculate that, in general, women with syphilis are 
screened less often.
Contrary to the well-established association of certain HPV 
types with development of cervical cancer (Muñoz et al, 1992), the 
humoral immune response against HPV remains to be clarified and 
fully characterized. As yet, there are no standardized serological 
assays to identify HPV infection.
The HPV-16 viral oncoproteins E6 and E7 bind to the products 
of tumor-suppressor genes and are the only viral proteins uniformly 
retained and expressed in cervical cancer cells, being capable of 
synergistically immortalizing human and rat cells in vitro (Watan- 
abe et a l,  1989). In fact, several studies have shown that antibodies 
to HP V-16 E7 are present at higher prevalence in sera from cervical
cancer patients than in those from healthy controls (Muller et al, 
1992). However, the clinical significance and HPV type specificity 
of these responses remain dubious.
In this study, we have analyzed sera from a subsample of cases 
with CIN and cervical carcinoma and from their control group for 
the presence of antibodies against a synthetic peptide containing 
known B-cell epitopes of HPV-16 E7, as well as for the presence of 
HPV DNA in cervical scrapes. In agreement with earlier studies 
(Muller et al, 1992), our results indicate that anti-E7 antibodies 
were associated independently with cervical cancer cases. In this 
group, we detected an overall prevalence rate of antibodies against 
peptide E7/6-35 of 22.4% among cases vs. 13.7% among controls 
for an adjusted OR of 3.6 (95% Cl 1.0-12.9), No significant 
differences were found for seroreactivity between patients with 
different grades of CIN. Baay et a l  (1995), using HPV-16 E7 
synthetic peptide in an ELISA identical to ours, found a prevalence 
rate of 17.7% in patients with cervical cancer in a study correlating 
clinicopathological parameters and antibody status to HPV-16 E7 
protein. In a similar way, Muller et a l  (1992), using a synthetic 
peptide also comprising amino acids 6-35, reported a prevalence 
rate of 37% in HPV-16 DNA-positive cervical cancer patients. In 
our current study, despite the higher prevalence of E7 reactivity 
among HPV-16 DNA-positive cervical cancer patients (33%), the 
correlation between HPV DNA status and the presence of anti- 
HPV-16 antibodies remained low (data not shown). We can infer 
from this last finding that only a proportion of HPV-16-infected 
individuals generate antibodies to this type-specific reactive epi­
tope of the E7 protein, which in turn reflects the still unclear 
dynamics of seroreactivity to HPV infections.
Even though antibodies to C. trachomatis and T. pallidum 
showed the strongest associations, although statistically not signifi­
cant with cervical cancer, our results are not consistent enough for 
drawing conclusions as to the STA other than HPV with which 
cervical cancer is associated most specifically. However, it cannot 
be excluded that genital infections with other STAs may play a 
separate etiological role in cervical carcinogenesis, and more 
definite conclusions would require a study of much larger popula­
tions. Furthermore, our data imply that even though E7 antibodies 
can help discriminate between cancer patients and minor dyspla­
sias, further studies are needed to map more specific epitopes that 
will define more clearly clinical and HPV type specificity.
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